← Leaderboards
Jacqueline Jonklaas
Georgetown University
$2,522,543
Attributed
$4,245,652
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $767.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,245,652 · 18
By mechanism
R01$2,025,262 · 2
UH3$767,922 · 1
K23$681,480 · 1
UG3$653,035 · 1
M01$117,953 · 13
Top collaborators
- Kristi Dove Graves8 shared
- Kenneth D Burman2 shared
Most similar at Georgetown University
Same institution · by research overlap
- Beth L Roman$5,559,876
- Bidhan Chandra Bandyopadhyay$1,468,619
- Kenneth D Burman$358,718
Others in their field
Top investigators on “Malignant Neoplasm Of Thyroid”
- David Heimbrook · Leidos Biomedical Research, Inc.$89,819,252
- James A Fagin · Sloan-Kettering Inst Can Research$18,343,965
- Keri Hammel · The Emmes Company, Llc$17,992,237
- Stanley R Hamilton · Johns Hopkins University$17,360,724
- Larry Arthur$15,377,757
- Ignacio I. Wistuba · Ut Southwestern Medical Center$15,303,923
Research focus
Malignant Neoplasm Of ThyroidSerumClinical ResearchDoseUnited StatesSymptomsCancer SurvivorPhysiciansRecurrenceQuality Of LifeLacrimalInstitutionGrantRadioactive IodineHigh RiskEvaluationCancer PatientComputer Retrieval Of Information On Scientific Projects DatabaseFrequenciesFaceDental CariesFundingHypothyroidismNewly Diagnosed
Grant awards (28)
Use of a decision aid to resolve uncertainty about radioactive iodine treatment in patients with intermediate-risk thyroid cancer: the Radiance trial$767,922
UH3 · FY2025 · DE · contact PI
Use of a decision aid to resolve uncertainty about radioactive iodine treatment in patients with intermediate-risk thyroid cancer: the Radiance trial$312,158
UG3 · FY2023 · DE · contact PI
Use of a decision aid to resolve uncertainty about radioactive iodine treatment in patients with intermediate-risk thyroid cancer: the Radiance trial$340,877
UG3 · FY2022 · DE · contact PI
Capturing the Impact of Craniofacial Damage after Radioiodine Therapy$354,815
R01 · FY2020 · DE · contact PI
Capturing the Impact of Craniofacial Damage after Radioiodine Therapy$327,110
R01 · FY2019 · DE · contact PI
Capturing the Impact of Craniofacial Damage after Radioiodine Therapy$276,027
R01 · FY2018 · DE · contact PI
Capturing the Impact of Craniofacial Damage after Radioiodine Therapy$155,500
R01 · FY2017 · DE · contact PI
Capturing the Impact of Craniofacial Damage after Radioiodine Therapy$194,375
R01 · FY2016 · DE · contact PI
Hyopthyroidism Treatment in Aging and Thyroid Cancer$368,861
R01 · FY2014 · AG · contact PI
Hyopthyroidism Treatment in Aging and Thyroid Cancer$348,574
R01 · FY2013 · AG · contact PI
SERUM SELENIUM LEVELS AND THYROID CANCER DEVELOPMENT$10,360
M01 · FY2009 · RR · contact PI
COMPARISON OF THYROID HORMONE LEVELS FOUND WITH NORMAL THYROID FUNCTIONING, C$15,802
M01 · FY2008 · RR · contact PI
IDENTIFICATION OF LEUKOCYTE GENES THAT ARE REGULATED BY THYROID HORMONE$9,989
M01 · FY2008 · RR · contact PI
SERUM SELENIUM LEVELS AND THYROID CANCER DEVELOPMENT$2,853
M01 · FY2008 · RR · contact PI
COMPARISON OF THYROID HORMONE LEVELS FOUND WITH NORMAL THYROID FUNCTIONING, C$24,536
M01 · FY2007 · RR · contact PI
IDENTIFICATION OF LEUKOCYTE GENES THAT ARE REGULATED BY THYROID HORMONE$1,907
M01 · FY2007 · RR · contact PI
COMPARISON OF CORTISON LEVELS DURING AN ACTH STIMULATION TEST USING TANDEM MASS$1,271
M01 · FY2007 · RR · contact PI
MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AWARD$141,480
K23 · FY2006 · RR · contact PI
COMPARISON OF THYROID HORMONE LEVELS FOUND WITH NORMAL THYROID FUNCTIONING, C$21,684
M01 · FY2006 · RR · contact PI
IDENTIFICATION OF LEUKOCYTE GENES THAT ARE REGULATED BY THYROID HORMONE$3,098
M01 · FY2006 · RR · contact PI
MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AWARD$141,480
K23 · FY2005 · RR
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY FOR HYPOTHYROIDISM$12,944
M01 · FY2005 · RR
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY FOR HYPOTHYROIDISM$6,470
M01 · FY2005 · RR
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY FOR HYPOTHYROIDISM$3,882
M01 · FY2005 · RR
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY$141,480
K23 · FY2004 · RR
Thyroid hormone levels with normal thyroid to level after thyroidectomy$3,157
M01 · FY2004 · RR
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY$128,520
K23 · FY2003 · RR
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY$128,520
K23 · FY2002 · RR